Which has preferable earnings and valuation, IFRX or MGTX?

InflaRx has higher earnings, but lower revenue than MeiraGTx. InflaRx is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 7,859.73 -$51.63M -$0.58 N/A MeiraGTx $81.39M 12.61 -$114.20M $0.71 15.06

Is IFRX or MGTX more profitable?

MeiraGTx has a net margin of 19.87% compared to InflaRx's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% MeiraGTx 19.87% 283.85% 29.39%

Is IFRX or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Janux Therapeutics N/A -11.89% -11.13%

Is IFRX or ODTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Odyssey Therapeutics N/A N/A N/A

Which has higher valuation & earnings, IFRX or SVRA?

InflaRx has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 7,859.73 -$51.63M -$0.58 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is IFRX or SVRA more profitable?

InflaRx's return on equity of -53.56% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Savara N/A -90.28% -68.95%

Which has stronger earnings and valuation, IFRX or ANL?

Adlai Nortye has higher revenue and earnings than InflaRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 7,859.73 -$51.63M -$0.58 N/A Adlai Nortye $5M 201.19 -$35.53M N/A N/A

Is IFRX or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Adlai Nortye N/A N/A N/A

InflaRx (IFRX) Competitors

$1.60 +0.07 (+4.58%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.60 -0.01 (-0.31%)

As of 10/9/2026 07:30 PM Eastern

Compare

IFRX vs. MGTX, JANX, ODTX, SVRA, and ANL

Should you buy InflaRx stock or one of its competitors? InflaRx's main competitors and comparable companies include MeiraGTx (MGTX), Janux Therapeutics (JANX), Odyssey Therapeutics (ODTX), Savara (SVRA), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does InflaRx compare to MeiraGTx?

InflaRx (NASDAQ:IFRX) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

MeiraGTx has a net margin of 19.87% compared to InflaRx's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
MeiraGTx	19.87%	283.85%	29.39%

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, MeiraGTx had 5 more articles in the media than InflaRx. MarketBeat recorded 6 mentions for MeiraGTx and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.61 beat MeiraGTx's score of 0.48 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Positive
MeiraGTx	Neutral

InflaRx presently has a consensus target price of $7.43, suggesting a potential upside of 364.29%. MeiraGTx has a consensus target price of $24.71, suggesting a potential upside of 131.19%. Given InflaRx's higher possible upside, equities research analysts plainly believe InflaRx is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

InflaRx has higher earnings, but lower revenue than MeiraGTx. InflaRx is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,859.73	-$51.63M	-$0.58	N/A
MeiraGTx	$81.39M	12.61	-$114.20M	$0.71	15.06

Summary

MeiraGTx beats InflaRx on 9 of the 15 factors compared between the two stocks.

How does InflaRx compare to Janux Therapeutics?

InflaRx (NASDAQ:IFRX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Janux Therapeutics had 4 more articles in the media than InflaRx. MarketBeat recorded 5 mentions for Janux Therapeutics and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.61 beat Janux Therapeutics' score of 0.57 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Positive
Janux Therapeutics	Positive

42.4% of InflaRx shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Janux Therapeutics' return on equity of -11.89% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Janux Therapeutics	N/A	-11.89%	-11.13%

InflaRx has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,859.73	-$51.63M	-$0.58	N/A
Janux Therapeutics	$10M	112.44	-$113.62M	-$1.64	N/A

InflaRx presently has a consensus target price of $7.43, indicating a potential upside of 364.29%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 98.27%. Given InflaRx's higher probable upside, analysts clearly believe InflaRx is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

InflaRx has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

Summary

InflaRx beats Janux Therapeutics on 8 of the 14 factors compared between the two stocks.

How does InflaRx compare to Odyssey Therapeutics?

InflaRx (NASDAQ:IFRX) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Odyssey Therapeutics had 7 more articles in the media than InflaRx. MarketBeat recorded 8 mentions for Odyssey Therapeutics and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.61 beat Odyssey Therapeutics' score of 0.52 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Positive
Odyssey Therapeutics	Positive

InflaRx currently has a consensus price target of $7.43, indicating a potential upside of 364.29%. Odyssey Therapeutics has a consensus price target of $37.00, indicating a potential upside of 94.74%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Odyssey Therapeutics has lower revenue, but higher earnings than InflaRx. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,859.73	-$51.63M	-$0.58	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Odyssey Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Odyssey Therapeutics	N/A	N/A	N/A

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

InflaRx beats Odyssey Therapeutics on 8 of the 12 factors compared between the two stocks.

How does InflaRx compare to Savara?

InflaRx (NASDAQ:IFRX) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

InflaRx has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,859.73	-$51.63M	-$0.58	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

InflaRx currently has a consensus price target of $7.43, indicating a potential upside of 364.29%. Savara has a consensus price target of $10.25, indicating a potential upside of 108.33%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Savara had 5 more articles in the media than InflaRx. MarketBeat recorded 6 mentions for Savara and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.61 beat Savara's score of 0.32 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Positive
Savara	Neutral

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

InflaRx's return on equity of -53.56% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Savara	N/A	-90.28%	-68.95%

InflaRx has a beta of 2.59, meaning that its share price is 159% more volatile than the broader market. Comparatively, Savara has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Summary

InflaRx beats Savara on 9 of the 13 factors compared between the two stocks.

How does InflaRx compare to Adlai Nortye?

InflaRx (NASDAQ:IFRX) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adlai Nortye's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Adlai Nortye	N/A	N/A	N/A

InflaRx presently has a consensus target price of $7.43, indicating a potential upside of 364.29%. Adlai Nortye has a consensus target price of $29.50, indicating a potential upside of 88.86%. Given InflaRx's higher probable upside, equities analysts plainly believe InflaRx is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Adlai Nortye has higher revenue and earnings than InflaRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,859.73	-$51.63M	-$0.58	N/A
Adlai Nortye	$5M	201.19	-$35.53M	N/A	N/A

InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

In the previous week, Adlai Nortye had 6 more articles in the media than InflaRx. MarketBeat recorded 7 mentions for Adlai Nortye and 1 mentions for InflaRx. Adlai Nortye's average media sentiment score of 0.62 beat InflaRx's score of 0.61 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
InflaRx	Positive
Adlai Nortye	Positive

Summary

Adlai Nortye beats InflaRx on 7 of the 12 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$235.79M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-2.76	13.55	275.01	26.14
Price / Sales	7,859.73	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	2.46	17.17	11.22	6.33
Net Income	-$51.63M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-6.98%	-1.34%	-0.89%	-1.40%
1 Month Performance	-23.44%	-8.04%	-4.02%	-3.35%
1 Year Performance	15.94%	14.18%	7.13%	1.49%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	1.8564 of 5 stars	$1.60 +4.6%	$7.43 +364.3%	+15.9%	$235.79M	$30K	N/A	65
MGTX MeiraGTx	3.0707 of 5 stars	$10.83 +1.6%	$24.71 +128.2%	+36.4%	$1.04B	$81.39M	15.26	393	Analyst Upgrade Insider Trade
JANX Janux Therapeutics	2.5325 of 5 stars	$16.93 -0.2%	$36.46 +115.4%	-30.6%	$1.03B	$10M	N/A	113	News Coverage
ODTX Odyssey Therapeutics	2.8952 of 5 stars	$20.66 +1.2%	$35.75 +73.0%	N/A	$992.92M	N/A	N/A	100	News Coverage Analyst Forecast
SVRA Savara	2.1721 of 5 stars	$4.81 -4.9%	$10.00 +108.1%	+46.0%	$987.24M	N/A	N/A	70	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors

IFRX vs. MGTX, JANX, ODTX, SVRA, and ANL

How does InflaRx compare to MeiraGTx?

Summary

How does InflaRx compare to Janux Therapeutics?

Summary

How does InflaRx compare to Odyssey Therapeutics?

Summary

How does InflaRx compare to Savara?

Summary

How does InflaRx compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InflaRx (IFRX) Competitors

IFRX vs. MGTX, JANX, ODTX, SVRA, and ANL

How does InflaRx compare to MeiraGTx?

Is IFRX or MGTX more profitable?

Do institutionals and insiders hold more shares of IFRX or MGTX?

Which has more volatility & risk, IFRX or MGTX?

Does the media favor IFRX or MGTX?

Do analysts rate IFRX or MGTX?

Which has preferable earnings and valuation, IFRX or MGTX?

Summary

How does InflaRx compare to Janux Therapeutics?

Does the media refer more to IFRX or JANX?

Do institutionals and insiders have more ownership in IFRX or JANX?

Is IFRX or JANX more profitable?

Which has higher valuation and earnings, IFRX or JANX?

Do analysts rate IFRX or JANX?

Which has more risk & volatility, IFRX or JANX?

Summary

How does InflaRx compare to Odyssey Therapeutics?

Does the media refer more to IFRX or ODTX?

Do analysts prefer IFRX or ODTX?

Which has higher earnings and valuation, IFRX or ODTX?

Is IFRX or ODTX more profitable?

Do institutionals & insiders believe in IFRX or ODTX?

Summary

How does InflaRx compare to Savara?

Which has higher valuation & earnings, IFRX or SVRA?

Do analysts recommend IFRX or SVRA?

Does the media favor IFRX or SVRA?

Do insiders & institutionals believe in IFRX or SVRA?

Is IFRX or SVRA more profitable?

Which has more volatility and risk, IFRX or SVRA?

Summary

How does InflaRx compare to Adlai Nortye?

Do insiders and institutionals believe in IFRX or ANL?

Is IFRX or ANL more profitable?

Do analysts recommend IFRX or ANL?

Which has stronger earnings and valuation, IFRX or ANL?

Which has more risk & volatility, IFRX or ANL?

Does the media favor IFRX or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools